Table 4.
Weighted multivariable logistic regression analysis of multiple serum composite indicators and obstructive sleep apnea.
| Model I OR (95% CI) | P-value | Model II OR (95% CI) | P-value | Model III OR (95% CI) | P-value | |
|---|---|---|---|---|---|---|
| MHR | ||||||
| Q1 0.04–0.28 |
Ref | Ref | Ref | |||
| Q2 0.28–0.38 |
1.51 (1.20, 1.90) | 0.001 | 1.49 (1.19, 1.88) | 0.001 | 1.24 (0.99, 1.57) | 0.068 |
| Q3 0.38–0.52 |
1.54 (1.24, 1.92) | <0.001 | 1.46 (1.17, 1.81) | 0.001 | 1.06 (0.84, 1.34) | 0.636 |
| Q4 0.52–3.67 |
2.52 (2.05, 3.09) | <0.001 | 2.23 (1.79, 2.77) | <0.001 | 1.48 (1.18, 1.87) | 0.001 |
| PHR | ||||||
| Q1 30.06–135.82 |
Ref | Ref | Ref | |||
| Q2 135.82–179.28 |
1.33 (0.96, 1.84) | 0.095 | 1.36 (0.98, 1.87) | 0.067 | 1.16 (0.83,1.62) | 0.379 |
| Q3 179.28–231.67 |
1.70 (1.30, 2.23) | <0.001 | 1.75 (1.35, 2.28) | <0.001 | 1.31 (1.00, 1.72) | 0.057 |
| Q4 231.67–817.33 |
2.08 (1.66, 2.62) | <0.001 | 2.17 (1.70, 2.75) | <0.001 | 1.46 (1.14, 1.87) | 0.004 |
| NHHR | ||||||
| Q1 0.28–1.80 |
Ref | Ref | Ref | |||
| Q2 1.80–2.47 |
1.93 (1.47, 2.54) | <0.001 | 1.88 (1.41, 2.49) | <0.001 | 1.55 (1.51, 2.09) | 0.006 |
| Q3 2.47–3.31 |
2.15 (1.71, 2.69) | <0.001 | 1.97 (1.59, 2.44) | <0.001 | 1.53 (1.20, 1.96) | 0.001 |
| Q4 3.31–9.26 |
2.41 (1.90, 3.05) | <0.001 | 2.08 (1.63, 2.65) | <0.001 | 1.41 (1.08, 1.84) | 0.015 |
| AIP | ||||||
| Q1 (−1.25)–(−0.32) |
Ref | Ref | Ref | |||
| Q2 (−0.32)–(−0.11) |
1.87 (1.44, 2.43) | <0.001 | 1.73 (1.34, 2.24) | <0.001 | 1.44 (1.09, 1.89) | 0.013 |
| Q3 (−0.11)-0.13 |
2.40 (1.85, 3.10) | <0.001 | 2.09 (1.63, 2.67) | <0.001 | 1.49 (1.15, 1.94) | 0.005 |
| Q4 0.13–0.86 |
2.62 (2.09, 3.29) | <0.001 | 2.22 (1.72, 2.86) | <0.001 | 1.42 (1.07, 1.90) | 0.021 |
| UHR | ||||||
| Q1 0.01–0.07 |
Ref | Ref | Ref | |||
| Q2 0.07–0.10 |
1.71 (1.33, 2.20) | <0.001 | 1.61 (1.26, 2.04) | <0.001 | 1.18 (0.92, 1.52) | 0.204 |
| Q3 0.10–0.14 |
1.84 (1.37,2.46) | <0.001 | 1.69 (1.26, 2.26) | 0.001 | 1.09 (0.81, 1.48) | 0.563 |
| Q4 0.14–0.43 |
2.96 (2.30, 3.82) | <0.001 | 2.61 (2.09, 3.26) | <0.001 | 1.40 (1.13, 1.75) | 0.004 |
| RC/HDL | ||||||
| Q1 0.03–0.22 |
Ref | Ref | Ref | |||
| Q2 0.22–0.36 |
1.89 (1.48, 2.42) | <0.001 | 1.75 (1.36, 2.25) | <0.001 | 1.47 (1.13, 1.91) | 0.006 |
| Q3 0.36–0.62 |
2.49 (1.92, 3.22) | <0.001 | 2.18 (1.70, 2.79) | <0.001 | 1.55 (1.18, 2.03) | 0.003 |
| Q4 0.62–3.29 |
2.67 (2.12, 3.36) | <0.001 | 2.26 (1.75, 2.92) | <0.001 | 1.46 (1.09, 1.96) | 0.014 |
| SIRI | ||||||
| Q1 0.08–0.64 |
Ref | Ref | Ref | |||
| Q2 0.64–0.97 |
1.33 (1.05, 1.68) | 0.019 | 1.33 (1.06, 1.66) | 0.015 | 1.24 (0.99, 1.54) | 0.065 |
| Q3 0.97–1.46 |
1.27 (0.97, 1.66) | 0.089 | 1.23 (0.94, 1.63) | 0.116 | 1.01 (0.77, 1.32) | 0.942 |
| Q4 1.46–11.60 |
1.72 (1.38, 2.13) | <0.001 | 1.55 (1.22, 1.97) | 0.001 | 1.27 (1.01, 1.60) | 0.044 |
| CMI | ||||||
| Q1 0.03–0.27 |
Ref | Ref | Ref | |||
| Q2 0.27–0.48 |
1.78 (1.38, 2.31) | <0.001 | 1.60 (1.23, 2.09) | 0.001 | 1.26 (0.96, 1.67) | 0.108 |
| Q3 0.48–0.86 |
2.75 (2.13, 3.54) | <0.001 | 2.34(1.86,2.95) | <0.001 | 1.52 (1.17, 1.97) | 0.003 |
| Q4 0.86–5.22 |
2.82 (2.26, 3.51) | <0.001 | 2.40 (1.87, 3.) | <0.001 | 1.29 (0.96, 1.74) | 0.021 |
Model I: unadjusted model. Model II: adjusted for age, gender, race, education level, Marital, PIR. Model III: adjusted for variables in Model II plus drinking status, BMI, hypertension, diabetes status, CVD, physical activity level, smoking status; BMI, body mass index; PIR: family income-poverty ratio; MHR, Monocyte to HDL Ratio; PHR, Platelet to HDL Ratio; NHHR, Non-HDL to HDL Ratio; AIP, atherogenic Index of Plasma; UHR, Uric acid to HDL Ratio; RC/HDL, Remnant Cholesterol to HDL Ratio; SIRI, Systemic Inflammation Response Index; CMI, Cardiometabolic Index; CVD, cardiovascular disease; OR, odds ratio; 95% CI, 95% confidence interval.